Findings by Moser et al. [330] demonstrated a strong protective impact of TLR4 inhibition (TLR4 inhibitor TAK-242) in obesity-mediated outcomes involving the inflammation of microglia. Here, TLR4 is linked to obesity due to melanocortin 4 receptor deficiency.